Amylyx Pharmaceuticals, Inc.
AMLX
$15.01
-$0.75-4.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.47% | -13.10% | -207.84% | -712.42% | -14,232.14% |
| Total Depreciation and Amortization | -44.78% | -39.79% | -37.86% | -16.91% | 7.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.76% | -60.70% | -52.77% | 557.67% | 638.69% |
| Change in Net Operating Assets | -58.66% | 10.95% | -2.12% | 30.20% | 77.65% |
| Cash from Operations | -62.43% | -182.26% | -1,354.28% | -1,506.55% | -85.25% |
| Capital Expenditure | -7,258.01% | -4,069.39% | -3,331.38% | -2,829.90% | 67.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 167.44% | 204.31% | 77.88% | 20.07% | 120.63% |
| Cash from Investing | 56.81% | 172.10% | -15.46% | -17.81% | 120.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 65.12% | -40.47% | -66.21% | -69.52% | -99.03% |
| Repurchase of Common Stock | -71.23% | 7.11% | 40.27% | 46.18% | 41.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 54,888.68% | 5,054.35% | 2,401.10% | -90.18% | -99.80% |
| Foreign Exchange rate Adjustments | 33.02% | 1,221.74% | -424.00% | -373.75% | -24.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 343.84% | 90.63% | -296.57% | -185.52% | -327.79% |